Lysophosphatidylcholine (LPC) is a chemotactic lysolipid produced during inflammation by the hydrolytic action of phospholipase A 2 enzymes. LPC stimulates chemotaxis of T cells in vitro through activation of the G protein-coupled receptor, G2A. This has led to the proposition that G2A contributes to the recruitment of T cells to sites of inflammation and thus promotes chronic inflammatory autoimmune diseases associated with the generation and subsequent tissue infiltration of auto-antigen-specific effector T cells. However, one study suggests that G2A may negatively regulate T cell proliferative responses to antigen receptor engagement and thereby attenuates autoimmunity by reducing the generation of autoreactive T cells. To address the relative contribution of these G2A-mediated effects to the pathophysiology of T cell-mediated autoimmune disease, we examined the impact of G2A inactivation on the onset and severity of murine experimental autoimmune encephalomyelitis (EAE), a model of multiple sclerosis (MS). Wild type (G2A Comparable numbers of T cells were detected in spinal cords of G2A +/+ and G2A −/− mice. We conclude that the proposed anti-proliferative and chemotactic functions of G2A are not manifested in vivo and therefore therapeutic targeting of G2A is unlikely to be beneficial in the treatment of MS.
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Introduction
Regulatory pathways controlling the ability of T cells to migrate into sites of local inflammation are potential candidates for therapeutic inhibition in organ-specific autoimmune diseases such as multiple sclerosis (MS) and rheumatoid arthritis (RA). The migratory characteristics of different lymphocytes are conferred by their respective repertoire of surface-expressed chemotactic receptors (Ebert et al., 2005) . In addition to the large family of classical chemokines and chemokine receptors, pro-inflammatory lysolipids have gained recognition as important mediators of inflammatory cell migration through the activation of specific G protein-coupled receptors (GPCRs) (Graler and Goetzl, 2002) . The local generation of lysolipids in inflamed tissue is mediated primarily by the hydrolytic action of secretory phospholipase A 2 (sPLA 2 ) enzymes on membrane and lipoprotein phospholipids (Pruzanski et al., 2005; Touqui and Alaoui-El-Azher, 2001 ). Lysophosphatidylcholine (LPC) is a major proinflammatory lysolipid product of sPLA 2 (Kougias et al., 2006) 2 and is also liberated from cells undergoing apoptosis (Kim et al., 2002) . Both these processes can contribute to the increases in local concentrations of LPC in inflamed tissue.
LPC stimulates T cell chemotaxis through the activation of G2A (Radu et al., 2004) , a GPCR expressed on all major hemato-lymphoid cell-types (Parks et al., 2005) . It has therefore been proposed that G2A activation by proinflammatory lysolipids plays a role in the recruitment of T cells into inflammatory lesions and thereby promotes the onset and/or increases the severity of T cell-mediated inflammatory autoimmune diseases such as MS. In support of this notion, PLA 2 activity was shown to be high in MS lesions and its inhibition led to a significant reduction in the onset and progression of experimental autoimmune encephalomyelitis (EAE) in mice (Kalyvas and David, 2004; Pinto et al., 2003) . However, while the lysolipid-sensitive chemotactic action of G2A would be expected to exacerbate EAE by promoting T cell infiltration, the results of one previous study suggest that G2A may actually reduce the susceptibility of mice to autoimmunity (Le et al., 2001 ). This study compared G2A-deficient (G2A −/− ) and G2A-sufficient (G2A +/+ ) mice on mixed BALBc/ 129Sv genetic backgrounds and revealed an increased susceptibility of the former to a late-onset (N1 year old) systemic autoimmune syndrome with features of human systemic lupus erythematosus (SLE) (Le et al., Journal of Neuroimmunology 207 (2009) 18-23 
